RxDoctor Payments Data

Margaret Richardson Nixon, MD

Internal Medicine · Tifton, GANPI 1225033921

Payments from drug & device makers

$2,109in general payments, 2019–2025

Across 127 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$355
  • GSK$246
  • Novo Nordisk$232
  • Amgen$152
  • Sanofi-aventis U.S. LLC$140
  • AbbVie$128
  • plus $855 from 20 others

What the payments were for

  • Food & beverage$2,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,109 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$23,104
Medicare patients
100
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide180$252,350
OzempicSemaglutide208$237,129
LinzessLinaclotide67$78,070
EliquisApixaban67$65,149
JanuviaSitagliptin Phosphate75$64,743
FarxigaDapagliflozin Propanediol49$42,335
XareltoRivaroxaban38$28,522
LivaloPitavastatin Calcium35$23,022
MyrbetriqMirabegron24$22,460
UbrelvyUbrogepant16$16,043
ArexvyRsvpref3 Antigen/As01e/Pf47$12,054
Colesevelam Hcl34$8,992
ShingrixVaricella-Zoster Ge/As01b/Pf38$7,377
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$6,782
Tresiba Flextouch U-100Insulin Degludec13$6,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humalog$16$255,102195 claims
Novo NordiskOzempic$232$237,129208 claims
AbbVieLinzess, Ubrelvy$128$94,11383 claims
PfizerEliquis$41$65,14967 claims
MerckJanuvia$62$64,74375 claims
AstraZenecaFarxiga$38$42,33549 claims
Johnson & JohnsonXarelto$115$28,52238 claims
Astellas Pharma US IncMyrbetriq$355$22,46024 claims
GSKArexvy, Shingrix$246$19,43185 claims
Sanofi-aventis U.S. LLCLantus$140$5,67537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →